B01 Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma. Christine C. Alewine, National Cancer Institute, NIH, Bethesda, MD

B02 Tissue-specific innate lymphoid cells are novel targets for pancreatic cancer immunotherapy. Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, NY

B03 Targeting tumor-intrinsic metabolic node in pancreatic cancer causes tumor regression, remodels extracellular matrix, and sensitizes to anti-PD1 therapy. Sulagna Banerjee, University of Miami, Miami, FL

B04 Identification of T-cell receptors targeting mutant KRAS in pancreatic cancer. Adham S. Bear, University of Pennsylvania, Philadelphia, PA

B05 Paclitaxel protein bound plus gemcitabine plus cisplatin and paricalcitol neoadjuvant therapy for localized pancreatic ductal adenocarcinoma (PDAC). Erkut Borazanci, HonorHealth/TGen, Scottsdale/Phoenix, AZ

B06 The angiotensin receptor blocker and partial PPARγ agonist telmisartan inhibits the growth of pancreatic ductal adenocarcinoma. Yves Boucher, Massachusetts General Hospital, Harvard Medical School, Boston, MA

B07 Enhancing the effect of autophagy inhibition for pancreatic cancer treatment. Kirsten L. Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC

B08 STING and TLR independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody. Katelyn T. Byrne, Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

B09 GSK-3β blockade with 9-ING-41 in pancreas cancer: The 1801 phase 1/2 study. Benedito A. Carneiro, Lifespan Cancer Institute, Brown University, Providence, RI

B10 Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma. Eileen Carpenter1, Department of Gastroenterology, University of Michigan, Ann Arbor, MI

B11 circFOXK2 promotes tumor growth and metastasis of pancreatic ductal adenocarcinoma via complexing with YBX1 and hnRNPK. Yangchao Chen, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong

B13 Pilot trial of gemcitabine, nab-paclitaxel, metformin, and a standardized dietary supplement in patients with unresectable pancreatic cancer. Vincent Chung City of Hope, Duarte, CA
B14 CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX). Fiona Maxwell, Ipsen Bioinnovation, Abingdon, UK


B17 Long noncoding RNA growth arrest specific 5 (GASS) as a proliferation "brake" in aggressive population of CD133+ cells responsible for recurrence in PDAC. Brittany C. Durden, University of Miami, Miami, FL

B18 Defining the role of chromatin remodeling complexes in pancreatic cancer stem cells. Lesley Paige Ferguson, University of California San Diego, La Jolla, CA

B19 Targeting ATM to sensitize pancreatic cancer to immunotherapy and radiotherapy. Michael Green, University of Michigan, Ann Arbor, MI

B20 KrasG12D effector dependencies in the maintenance of pancreatic ductal adenocarcinoma. Adrien Grimont, Weill Cornell Medicine, New York, NY

B21 Pharmacologic activation of G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma. Christopher Natale, Linnaeus Therapeutics, Haddonfield, NJ

B22 Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441). Hagop Youssoufian, Erytech, Boston, MA

B23 Bioadhesive nanoparticles as a delivery vehicle in pancreatic cancer epithelial cells and pancreatic fibroblasts. Nesrin M. Hasan, Yale University, New Haven, CT

B24 Gastrointestinal microbiome changes in stage IV pancreatic cancer patients treated with pembrolizumab with or without paricalcitol on the Stand Up to Cancer (SU2C) Pancreas Catalyst Trial. Sarah K. Highlander, Translational Genomics Research Institute, Flagstaff, AZ

B25 Engrailed-1 promotes pancreatic cancer progression via antagonizing COMPASS activity. Chang-il Hwang, University of California Davis, Davis, CA

B26 Targeted and sustained drug delivery therapy for localized pancreatic cancer: In vivo validation in porcine models. Laura Indolfi, PanTher Therapeutics, Inc., Cambridge, MA

B27 A phase I/II trial of high-dose (HD) ascorbic acid (AA) + paclitaxel protein bound (PP) + cisplatin (C) + gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (MPC). Gayle S. Jameson, HonorHealth Research Institute, Scottsdale, AZ
Poster Session B  
Saturday, September 7  
1:30 p.m.-3:30 p.m.

**B28** Novel combination treatment designed to target both metastatic cells and proliferation in pancreatic ductal adenocarcinoma. Michelle Karl, Johns Hopkins University, Baltimore, MD

**B29** Outcomes of DNA repair-deficient pancreatic cancers: KU Cancer Center experience. Anup Kasi, University of Kansas, Kansas City, KS

**B30** Assessment of CCR5i/maraviroc immunotherapy in combination with PD1 and MR-guided radiotherapy for treatment of pancreatic cancer. Simone Lanfredini, University of Oxford, Oxford, United Kingdom

**B31** Type 1 conventional dendritic cells are progressively and systemically dysregulated early in pancreatic carcinogenesis. Jeffrey H. Lin, University of Pennsylvania, Philadelphia, PA

**B32** Mutant KRAS downregulates LIFR to enhance glycolysis in pancreatic cancer. Suhu Liu, Montefiore New Rochelle Hospital, New Rochelle, NY

**B33** Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma. Nune Markosyan, University of Pennsylvania, Philadelphia, PA

**B34** The impact of lymphocyte-to-monocyte ratio (LMR) in patients with borderline resectable pancreatic head cancer after curative surgery. Yoji Miyahara, Department of General Surgery, Chiba University, Chiba, Japan

**B35** Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX, ^2^University of Arizona Cancer Center, Tucson, AZ

**B36** Maintenance chemotherapy after chemoradiation in patients with locally advanced pancreatic cancer. Jonathan D. Mizrahi, University of Texas MD Anderson Cancer Center, Houston, TX

**B37** The complex immune-microenvironment heterogeneity in pancreatic cancer. Dana A. Mustafa, Erasmus MC, Rotterdam, The Netherlands

**B38** Calcium signaling induces a partial EMT in pancreatic ductal adenocarcinoma. Robert J. Norgard, University of Pennsylvania, Philadelphia, PA

**B40** High circulating CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): Biomarker analysis from the randomized phase II SCALOP trial. Eric O’Neill, Oxford University, Oxford, United Kingdom

**B41** Compartment deconvolution in pancreatic cancer with biologic and clinical implications. Xianlu L. Peng, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC

**B42** Patient stratification and precision medicine in pancreatic cancer: GemciTest, an innovative in vitro diagnostic for the decision-making process of pancreatic cancer treatment. Didier Ritter, Acobiom, Montpellier, France
**Poster Session B**  
**Saturday, September 7**  
1:30 p.m.-3:30 p.m.

**B43** p120 catenin loss drives pancreatic cancer EMT and metastasis through activation of PTHrP-mediated calcium signaling. Jason R. Pitirresi, University of Pennsylvania, Philadelphia, PA

**B44** Clinical utility of semiquantitative evaluation of progesterone receptor immunohistochemistry in neuroendocrine tumors of the pancreas. Sonya Purushothaman, Columbia Presbyterian Hospital, New York, NY

**B45** IL35/STAT3 axis as regulator of tolerance and T-cell exclusion in pancreatic cancer. Yuliya Pylayeva-Gupta, University of North Carolina at Chapel Hill, Chapel Hill, NC

**B46** Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734. Nikolina Radulovich, University Health Network, Toronto, ON, Canada

**B47** KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL. Cody Rozeveld, Mayo Clinic, Rochester, MN

**B48** Targeting the semaphorin 4D-plexin B axis to augment FOLFIRINOX in a murine model of pancreatic adenocarcinoma. Luis I. Ruffolo, University of Rochester Medical Center, Rochester, NY

**B49** Precision targeting of M2-like macrophages by the innate defense regulator RP-182 in pancreatic cancer and noncancerous diseases. Rushikesh Sable, National Cancer Institute, Bethesda, MD

**B50** Keratin 17 drives tumor aggression and could be targeted for treatment of pancreatic ductal adenocarcinoma. Kenneth R. Shroyer, Department of Pathology, Renaissance School of Medicine, Stony Brook, NY

**B51** Examining the differential cellular response of pancreatic cancer cell lines to 12C vs. photon irradiation. Brock J. Sishc, UT Southwestern Medical Center, Dallas, TX

**B52** The T-cell architecture of pancreatic ductal adenocarcinoma. Shivan Sivakumar, University of Oxford, Oxford, United Kingdom

**B54** The clinical impact and analysis for neoadjuvant chemotherapy against borderline resectable pancreatic cancer: Gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel. Shigetsugu Takano, Chiba University, Chiba, Japan

**B56** Endogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types. James T. Topham, Pancreas Centre BC, Vancouver, BC, Canada

**B57** Early-onset pancreatic ductal adenocarcinomas are characterized by a distinct mutational landscape. Erica S. Tsang, BC Cancer, Vancouver, BC, Canada

**B58** A phase I/II study of durvalumab and stereotactic radiotherapy in locally advanced pancreatic cancer. Richard Tuli, Memorial Sloan Kettering Cancer Center, New York, NY
B59 IL-6 regulates CTLA4 expression on CD4+ T-cells and dual antibody blockade of IL-6 and CTLA4 leads to tumor regression in an orthotopic murine model of pancreatic ductal adenocarcinoma. Michael B. Ware, Emory University, Atlanta, GA

B60 Optimization of biologic scheduling of gemcitabine and abraxane improves treatment response compared to the standard concurrent regimen in preclinical models of pancreatic cancer. Adam R. Wolfe, Ohio State James Cancer Center, Columbus, OH

B61 Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules. Keisuke Yamamoto, Department of Radiation Oncology, New York University School of Medicine, New York, NY

B62 Development of infectivity-selective oncolytic adenovirus for systemic cancer therapy. Masato Yamamoto, University of Minnesota, Minneapolis, MN